Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Can a protein drink help GLP-1 users keep muscle and avoid weight regain?

NCT ID NCT07595575

First seen May 19, 2026 · Last updated Jun 19, 2026 · Updated 6 times

Summary

This study tests whether special amino acid-enriched drinks can help people on GLP-1 weight-loss drugs maintain muscle and prevent weight regain. Eight adults aged 30-65 who recently started GLP-1 medication will drink different supplement beverages, and researchers will measure how their bodies process protein, sugar, and insulin. The goal is to learn if these supplements support muscle health during weight loss.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for OBESITY are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance

amino acid-enriched supplement beverages (Leuvate 001 and Leuvate 002)

What this could lead to

If successful, this could point toward a simple supplement to help people on GLP-1 drugs keep muscle and avoid regaining weight after stopping the medication.

What could go wrong

This is a very small, early study with only 8 people. It measures short-term body responses, not long-term weight or muscle outcomes, so results may not lead to practical advice.

Conditions

The condition(s) this trial relates to.

obesity disorder prediabetes syndrome type 2 diabetes mellitus

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.